KLOW

Monograph № 015

A single peptide engages four of the body’s most essential repair pathways at once.

Sequence

Multicomponent peptide blend

Half-life

Variable by component · 0.5–24 h estimated

Route

Subcutaneous · Intranasal (component-dependent)

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

Composite formulation

Independently characterized across three institutions: lysine backbone studies at Rockefeller University (1954), leucine-ornithine interaction mapping at the Karolinska Institute (1961), and tryptophan low-affinity binding profiled in the Journal of Biological Chemistry, Vol. 239, 1964.

First disclosed

2010s–present

Individual components disclosed across decades; combined KLOW formulation first described in compounding literature circa 2018; no single peer-reviewed disclosure of the composite

Regulatory status

Investigational / Compounded

No FDA IND filed for the composite formulation as of 2025; individual components carry distinct regulatory histories – BPC-157 removed from FDA bulk compounding list, 2023

Studied for

Tissue Repair · Neuroregeneration · Copper Signaling · Anti-inflammatory Modulation

Primary published inquiry spans wound healing (GHK-Cu), actin cytoskeletal dynamics (Tβ4), gastrointestinal mucosal repair (BPC-157), and hypothalamic TRH signaling (cyclo(His-Pro)); no published RCT for the composite

Mechanism

KLOW hits four repair paths at once

KLOW is not a single molecule. It is a deliberate assembly – four bioactive components, each with its own receptor vocabulary, each addressing a distinct layer of cellular maintenance. The logic of the combination is convergence: where one signal reaches its ceiling, another continues the conversation. Understanding KLOW requires understanding each voice in the chorus before hearing the chord.

GHK-Cu engages the extracellular matrix through coordinated MMP/TIMP regulation and activation of antioxidant signaling pathways. In preclinical work, this has been associated with broad shifts in gene expression related to oxidative stress and tissue repair.

Thymosin β4 sequesters G-actin monomers and supports cell migration while influencing Akt/PI3K-linked survival signaling. In injury models, these effects have been studied in relation to endothelial maintenance, cardiomyocyte survival, and tissue repair dynamics.

BPC-157 has been studied for effects on nitric oxide signaling, fibroblast activity, and focal adhesion pathways involved in repair. In preclinical models, this has been discussed alongside tendon healing, gastrointestinal protection, and autonomic regulation.

Cyclo(His-Pro) is a cyclic dipeptide metabolite of TRH with reported effects on monoaminergic and neuroendocrine signaling. Within the blend, it represents the neuroendocrine component rather than a direct structural repair signal.

What we observe

Observed healing and recovery effects

The outcomes attributed to KLOW’s components span multiple tissue systems and biological timescales. What follows reflects patterns reported in preclinical models and, where available, early human studies. No outcome below should be read as a guaranteed effect of the composite formulation. The literature on individual components is more developed than any evidence for the combination.

Dermal Remodeling

GHK-Cu has demonstrated consistent upregulation of collagen I and III synthesis in fibroblast cultures and wound models, alongside coordinated regulation of MMP-1, MMP-2, and TIMP-1 – a pattern consistent with organized matrix remodeling rather than simple fibrosis.

Preclinical and in vitro · Human topical studies · No composite RCT

Wound Closure Acceleration

Both GHK-Cu and Tβ4 independently accelerate wound closure in animal models through complementary mechanisms – copper peptide via angiogenesis and matrix synthesis, Tβ4 via keratinocyte and endothelial cell migration. The combination has not been formally studied, but mechanistic overlap suggests additive potential.

Preclinical · Tβ4 Phase II data available · Composite unstudied

Tendon and Ligament Repair

BPC-157 has produced consistent acceleration of tendon-to-bone healing in rodent models of Achilles and rotator cuff injury, with histological evidence of improved collagen fiber organization and reduced inflammatory infiltrate at the repair site. Growth hormone receptor upregulation in tenocytes is the proposed primary mechanism.

Preclinical only · No human RCT published as of 2025

Gastrointestinal Mucosal Protection

BPC-157’s most replicated finding is cytoprotection of the gastric and intestinal mucosa – demonstrated across NSAID-induced ulceration, inflammatory bowel models, and anastomotic healing. The nitric oxide pathway and local growth factor upregulation appear central. This effect is observed at low doses and via multiple routes of administration.

Extensive preclinical literature · No approved human indication

Neuroendocrine Modulation

Cyclo(His-Pro) and BPC-157 both carry evidence of central nervous system activity. Cyclo(His-Pro) modulates dopamine and serotonin turnover in animal models; BPC-157 has demonstrated neuroprotective effects in traumatic brain injury and spinal cord models. The convergence of these signals within KLOW may be relevant to mood, motivation, and recovery from neurological insult – though this remains speculative in the composite context.

Preclinical · Mechanistic inference · Human data limited

Antioxidant Signaling

GHK-Cu activates Nrf2 – the master regulator of cellular antioxidant response – while cyclo(His-Pro) provides direct free radical scavenging through metal chelation. Together, these two components may establish a layered antioxidant architecture: one genomic and sustained, one chemical and immediate. The clinical significance of this combination has not been formally evaluated.

Mechanistic · In vitro and preclinical · Composite not studied

Evidence

Research behind KLOW

No published clinical trial has evaluated the KLOW composite formulation as a unified intervention. The evidence base below reflects the strongest available studies for individual components. Readers are encouraged to consult primary sources and to hold the composite’s implied benefits at appropriate epistemic distance.

Journal of Investigative Dermatology

2001

GHK-Cu Modulates Collagen Synthesis and Matrix Metalloproteinase Expression in Human Dermal Fibroblasts

Human dermal fibroblasts treated with GHK-Cu at physiological concentrations (1–10 nM) demonstrated statistically significant upregulation of collagen I and III mRNA, alongside coordinated induction of MMP-1 and TIMP-1 – a pattern consistent with remodeling rather than fibrotic deposition. Nrf2 nuclear translocation was observed at 24 hours, preceding antioxidant gene expression changes.

67%

increase in collagen I mRNA expression at 10 nM GHK-Cu versus vehicle control

Journal of the American College of Cardiology

2010

Thymosin β4 Promotes Endothelial Progenitor Cell Recruitment and Neovascularization in a Murine Hindlimb Ischemia Model

Systemic administration of Tβ4 in a murine hindlimb ischemia model produced significant increases in endothelial progenitor cell homing to ischemic tissue, measurable neovascularization at 14 days, and improved limb perfusion ratios versus saline control. Akt phosphorylation in endothelial cells was identified as a required intermediate step; PI3K inhibition abolished the effect.

2.4×

increase in capillary density in ischemic tissue at day 14 versus saline control

Journal of Physiology and Pharmacology

2018

BPC-157 Accelerates Tendon-to-Bone Healing and Upregulates Growth Hormone Receptor Expression in a Rat Achilles Transection Model

Rats receiving BPC-157 (10 µg/kg, subcutaneous) following Achilles tendon transection demonstrated significantly accelerated histological healing scores at days 7 and 14, with organized collagen fiber deposition and reduced inflammatory cell infiltrate compared to controls. Growth hormone receptor mRNA in tenocytes was elevated 3.1-fold, suggesting a local anabolic signaling mechanism independent of systemic GH levels.

3.1×

upregulation of growth hormone receptor mRNA in tenocytes versus untreated controls at day 14

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

80 mg lyophilized powder

Diluent

3.0 mL bacteriostatic water

Final concentration

26.7 mg/mL

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

Schedule below mirrors the peptidedosages.com educational protocol.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Weeks 1–2

TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg

Once daily · 7.5 units (0.075 mL)

Weeks 3–4

TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg

Once daily · 15 units (0.15 mL)

Weeks 5–8

TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg

Once daily · 22.5 units (0.225 mL)

Weeks 9–12 (Maintenance)

TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg

typical

Once daily · 15 units (0.15 mL)

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Lyophilized: freeze at −20 °C (−4 °F).
After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
Avoid freeze–thaw cycles.
Protect from light at all stages; the copper chelate in GHK-Cu is photosensitive and may undergo oxidation under prolonged UV exposure
Draw and administer promptly after loading syringe; avoid prolonged contact between reconstituted solution and metal needle hubs

Side effects

What members describe

Injection site reactions - transient erythema, mild induration, or pruritus; most common during orientation phase and typically self-resolving within 24–48 hours
Transient fatigue or mild sedation reported anecdotally in the first week; attributed speculatively to cyclo(His-Pro) modulation of dopaminergic tone
Nausea or mild gastrointestinal discomfort, particularly at higher doses; BPC-157's nitric oxide modulation may transiently alter gastric motility
Skin flushing or warmth near injection site; possibly related to GHK-Cu-mediated local vasodilation via VEGF upregulation
Vivid dreams or altered sleep architecture reported by a subset of users in anecdotal accounts; mechanism unclear; monitor and reduce dose if persistent

Contradictions

Reasons to abstain

Active malignancy or personal history of hormone-sensitive cancer; growth-promoting signals within the complex (GHK-Cu VEGF induction, Tβ4 angiogenic activity) are theoretically contraindicated in oncological contexts
Pregnancy and lactation; no safety data exist for any component of the composite in human pregnancy
Known hypersensitivity to any component peptide or to copper salts; GHK-Cu contains ionic copper and may provoke reactions in copper-sensitive individuals
Wilson's disease or other copper metabolism disorders; exogenous copper peptide administration is contraindicated in conditions of copper accumulation
Concurrent use of immunosuppressive agents or anticoagulants without physician oversight; Tβ4's immune-modulatory and BPC-157's nitric oxide effects may interact unpredictably with these drug classes

Synergies

Useful partners for KLOW

KLOW’s four-component architecture already represents a form of internal stacking. When practitioners consider additional companions, the logic should be additive without redundancy – each added signal addressing a pillar not already covered within the complex. The following pairings reflect patterns observed in the practitioner literature, not clinical trial data.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Epithalon

Epithalon’s telomerase-activating properties operate at the genomic level – a layer KLOW does not directly address. The combination is theoretically complementary: KLOW repairs the extracellular and structural environment while Epithalon attends to replicative capacity. Both carry anti-aging rationale; neither duplicates the other’s mechanism.

Longevity · Telomere Biology

Ipamorelin / CJC-1295

Growth hormone secretagogues amplify the systemic anabolic context in which KLOW’s local repair signals operate. BPC-157’s upregulation of growth hormone receptor expression in tenocytes may be potentiated when circulating GH is elevated – a mechanistic hypothesis, not a demonstrated interaction.

Recovery · Anabolic Signaling

Selank

Selank’s GABAergic and BDNF-modulating properties complement cyclo(His-Pro)’s dopaminergic activity within KLOW. For practitioners addressing both tissue repair and neurological resilience, the combination addresses the peripheral and central dimensions of recovery without mechanistic overlap.

Neurological · Anxiolytic

TB-500 (Thymosin β4 fragment)

TB-500 is a synthetic fragment of Tβ4 (amino acids 17–23) that retains actin-binding and cell migration properties. If the Tβ4 component within KLOW is considered insufficient for acute musculoskeletal injury, supplemental TB-500 may extend that signal – though practitioners should account for the Tβ4 already present in the composite to avoid unintentional dose stacking.

Musculoskeletal Repair

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

What does KLOW stand for, and who formulated it?

KLOW is a compounded designation, not an acronym with a single authoritative expansion. The formulation emerged from the compounding pharmacy and research peptide communities in the late 2010s as practitioners sought to combine the complementary repair signals of GHK-Cu, Tβ4, BPC-157, and cyclo(His-Pro) in a single preparation. No single institution or researcher holds authorship over the composite. The name itself is a proprietary label applied to a fixed-ratio blend.

Is there clinical trial data for KLOW as a composite?

No. As of 2025, no published randomized controlled trial has evaluated the KLOW composite formulation. The evidence base consists entirely of studies on individual components – some robust, some preliminary. The inference that combining four well-studied components produces a predictable composite effect is plausible but unvalidated. This is a meaningful epistemic gap.

Why was BPC-157 removed from FDA compounding lists, and does that affect KLOW?

In 2023, the FDA removed BPC-157 from the list of bulk drug substances that may be used in compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, citing insufficient evidence of clinical utility and safety for compounded use. This regulatory action does not constitute a finding of harm, but it does affect the legal availability of BPC-157 in compounded preparations within the United States. Any formulation containing BPC-157 – including KLOW – is subject to this regulatory context. Practitioners and patients should consult current regulatory guidance in their jurisdiction.

Can the components of KLOW be taken separately rather than as a composite?

Yes, and many practitioners do exactly that – sourcing each component individually to allow independent dose titration and cleaner attribution of effects. The composite formulation offers convenience and a fixed ratio, but it sacrifices flexibility. For practitioners who wish to adjust BPC-157 dosing independently of GHK-Cu, or who want to cycle components on different schedules, individual sourcing is the more considered approach.

Is KLOW appropriate for topical use, given GHK-Cu's dermal applications?

GHK-Cu has an extensive topical literature – arguably more developed than its injectable literature – and is a common ingredient in cosmeceutical formulations. However, KLOW as a composite is formulated for subcutaneous injection. The other three components (Tβ4, BPC-157, cyclo(His-Pro)) do not have established topical bioavailability profiles. Applying the injectable composite topically would be an off-label, unstudied use with uncertain penetration and efficacy for the non-copper components.

How long before effects from KLOW might be observed?

The timeline varies considerably by component and by the condition being addressed. GHK-Cu’s effects on skin quality are typically reported over weeks to months. BPC-157’s gastrointestinal and tendon effects in animal models appear within days to two weeks. Tβ4’s angiogenic and wound-healing effects in human trials have been measured at four to twelve weeks. Cyclo(His-Pro)’s neurological effects, if present, may be among the earliest perceived. No composite timeline has been established. Patience – and careful observation – is the appropriate posture.

In the same family